文献速递白血病造血干细胞移植与细胞治疗

围移植期可测量残留病灶阈值对NPM1突变急性髓系白血病的预测能力

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

该回顾性研究分析了2家德国中心172例接受异基因造血细胞移植的NPM1突变急性髓系白血病患者,发现移植前MRD阴性是长期总生存期的强预测因素,而移植后第30天MRD阳性与阴性者总生存期相当;基于移植前及移植后第30天和第100天MRD纵向整合的联合风险评分可有效分层总生存期,预测能力优于年龄、FLT3-ITD状态或形态学缓解状态。

要点

  • 移植前NPM1-MRD阴性是长期总生存期的强预测因素。
  • 移植后第30天NPM1-MRD阳性与阴性患者的总生存期相当。
  • 基于移植前及移植后第30天和第100天MRD的联合评分可分层2年总生存期(100%、90.1%、57.1%、25.7%;P< .0001)。

核心结论

  • 在围移植期,NPM1-MRD阈值优于基于二分类或对数步长变化数据的传统MRD分析。

研究设计与样本

  • 回顾性分析2家德国中心172例接受异基因造血细胞移植的NPM1突变急性髓系白血病患者,探讨移植前后NPM1-MRD的预测价值。

主要发现

  • 移植前MRD阴性是良好长期总生存期的强预测因素。
  • 移植后第30天NPM1-MRD阳性与阴性患者的总生存期相当。
  • 基于移植前及移植后第30天MRD的联合评分用于指导早期减少免疫抑制(一致性指数0.737)。
  • 基于移植前及移植后第30天和第100天MRD的联合评分用于指导移植后后期干预(一致性指数0.841;分层2年总生存期分别为100%、90.1%、57.1%和25.7%;P< .0001)。
  • 该联合评分对总生存期的预测优于年龄、FLT3-ITD状态或形态学缓解状态。

关键数值与推荐

  • 移植前及移植后第30天MRD联合评分的一致性指数为0.737。
  • 移植前及移植后第30天和第100天MRD联合评分的一致性指数为0.841,分层2年总生存期分别为100%、90.1%、57.1%和25.7%(P< .0001)。

临床怎么用

  • 作者提出在围移植期,NPM1-MRD阈值优于基于二分类或对数步长变化数据的传统MRD分析。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) monitoring for mutated NPM1 is increasingly used to guide treatment decisions in patients with acute myeloid leukemia (AML) carrying this mutation. NPM1-MRD positivity after induction has been shown to identify patients who may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), and NPM1-MRD monitoring after allo-HCT can detect early relapse, enabling the prompt initiation of salvage therapy. However, recommendations for clinical decision-making based on peritransplant NPM1-MRD levels are missing. In this study, we retrospectively analyzed 172 patients with NPM1-mutant AML treated at 2 German centers to explore the predictive values of NPM1-MRD measured before and after allo-HCT. We found that pretransplant MRD negativity was a strong predictor of favorable long-term overall survival (OS). In contrast, patients with positive and negative NPM1-MRD status at day 30 after HCT showed comparable OS. Finally, statistically derived NPM1-MRD thresholds effectively stratified MRD-high and MRD-low patient groups with differential outcome, with 2 peritransplant MRD risk scores obtained by longitudinal integration. First, a combined score using MRD measurements before HCT and at day 30 HCT was used to guide early reduction of immunosuppression (concordance index [C-index], 0.737). Second, a combined score using MRD measurements before HCT and at day 30 and day 100 after HCT was used to guide later post-HCT interventions (C-index, 0.841; stratified 2-year OS groups, 100%, 90.1%, 57.1%, and 25.7%; P< .0001). This approach predicted OS better than age, FLT3-ITD status, or morphological remission status. We propose that in the peritransplant setting, NPM1-MRD thresholds are superior to conventional MRD analysis based on binary or log-step change data.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schroeder JC, Schwartz F, Metzdorf J, et al. Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia. Blood Adv. 2026. PMID: 41289166. doi:10.1182/bloodadvances.2025017908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。